{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:28:43Z","timestamp":1781072923415,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Child Adolesc Psychiatry Ment Health"],"DOI":"10.1186\/s13034-026-01060-1","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:25:01Z","timestamp":1772969101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unusual experiences and early-onset psychosis associated to hallucinogen use in adolescents: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Maite","family":"Armanino-Irigaray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Catal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Aymerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Pedruzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Arg\u00fcelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alazne","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Armyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Gonz\u00e1lez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Salazar de Pablo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"4","key":"1060_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/jcpp.14088","volume":"66","author":"I Kelleher","year":"2025","unstructured":"Kelleher I. Annual Research Review: Psychosis in children and adolescents: key updates from the past 2 decades on psychotic disorders, psychotic experiences, and psychosis risk. J Child Psychol Psychiatry. 2025;66(4):460\u201376.","journal-title":"J Child Psychol Psychiatry"},{"issue":"3","key":"1060_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/wps.20440","volume":"16","author":"MJ Owen","year":"2017","unstructured":"Owen MJ, O\u2019Donovan MC. Schizophrenia and the neurodevelopmental continuum:evidence from genomics. World Psychiatry. 2017;16(3):227\u201335.","journal-title":"World Psychiatry"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"14005","DOI":"10.1038\/npjschz.2014.5","volume":"1","author":"CM Diaz-Caneja","year":"2015","unstructured":"Diaz-Caneja CM, Pina-Camacho L, Rodriguez-Quiroga A, Fraguas D, Parellada M, Arango C. Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr. 2015;1:14005.","journal-title":"NPJ Schizophr"},{"issue":"1","key":"1060_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1192\/bjp.2022.203","volume":"223","author":"G Salazar de Pablo","year":"2023","unstructured":"Salazar de Pablo G, Catalan A, Vaquerizo Serrano J, Pedruzo B, Alameda L, Sandroni V, et al. Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis. Br J Psychiatry. 2023;223(1):282\u201394.","journal-title":"Br J Psychiatry"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-244X-10-63","volume":"10","author":"YC Kao","year":"2010","unstructured":"Kao YC, Liu YP. Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. BMC Psychiatry. 2010;10:63.","journal-title":"BMC Psychiatry"},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.euroneuro.2024.02.005","volume":"82","author":"CU Correll","year":"2024","unstructured":"Correll CU, Arango C, Fagerlund B, Galderisi S, Kas MJ, Leucht S. Identification and treatment of individuals with childhood-onset and early-onset schizophrenia. Eur Neuropsychopharmacol. 2024;82:57\u201371.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1060_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/jcpp.12783","volume":"59","author":"KM Gray","year":"2018","unstructured":"Gray KM, Squeglia LM. Research Review: What have we learned about adolescent substance use? J Child Psychol Psychiatry. 2018;59(6):618\u201327.","journal-title":"J Child Psychol Psychiatry"},{"key":"1060_CR8","unstructured":"Agency EUD. Key findings from the 2024 European school survey project on alcohol and other drugs (ESPAD). European Union Drugs Agency; 2025."},{"key":"1060_CR9","volume-title":"Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021","author":"SAMHS Administration","year":"2024","unstructured":"Administration SAMHS. Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021. NSDUH Series H-59. Substance Abuse and Mental Health Services Administration: Center for Behavioral Health Statistics and Quality; 2024."},{"issue":"2","key":"1060_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/10550887.2024.2332512","volume":"43","author":"S Turan","year":"2025","unstructured":"Turan S, Ermis C, Eray S, Agac N, Karakus OB, Saglam Y, et al. Illness-related outcomes of illicit substance use disorder in adolescents with early onset schizophrenia: a multicenter study. J Addict Dis. 2025;43(2):141\u20135.","journal-title":"J Addict Dis"},{"issue":"2","key":"1060_CR11","first-page":"305","volume":"53","author":"SL Matheson","year":"2023","unstructured":"Matheson SL, Laurie M, Laurens KR. Substance use and psychotic-like experiences in young people: a systematic review and meta-analysis. Psychol Med. 2023;53(2):305\u201319.","journal-title":"Psychol Med"},{"issue":"4","key":"1060_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","volume":"3","author":"FX Vollenweider","year":"2001","unstructured":"Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci. 2001;3(4):265\u201379.","journal-title":"Dialogues Clin Neurosci"},{"issue":"4","key":"1060_CR13","doi-asserted-by":"publisher","first-page":"100059","DOI":"10.1016\/j.pharmr.2025.100059","volume":"77","author":"BR Cummins","year":"2025","unstructured":"Cummins BR, Billac GB, Nichols DE, Nichols CD. 5-HT(2A) receptors: Pharmacology and functional selectivity. Pharmacol Rev. 2025;77(4):100059.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"1060_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE, Hallucinogens. Pharmacol Ther. 2004;101(2):131\u201381.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1060_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199\u2013214.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"1060_CR16","first-page":"917","volume":"165","author":"H Kalant","year":"2001","unstructured":"Kalant H. The pharmacology and toxicology of ecstasy (MDMA) and related drugs. CMAJ. 2001;165(7):917\u201328.","journal-title":"CMAJ"},{"issue":"4","key":"1060_CR17","first-page":"381","volume":"11","author":"NS Mustafa","year":"2020","unstructured":"Mustafa NS, Bakar NHA, Mohamad N, Adnan LHM, Fauzi N, Thoarlim A, et al. MDMA and the Brain: A Short Review on the Role of Neurotransmitters in Neurotoxicity. Basic Clin Neurosci. 2020;11(4):381\u20138.","journal-title":"Basic Clin Neurosci"},{"issue":"6","key":"1060_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/17470919.2015.1136355","volume":"11","author":"MC Wardle","year":"2016","unstructured":"Wardle MC, Bershad AK, de Wit H. Naltrexone alters the processing of social and emotional stimuli in healthy adults. Soc Neurosci. 2016;11(6):579\u201391.","journal-title":"Soc Neurosci"},{"issue":"3","key":"1060_CR19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41380-024-02800-5","volume":"30","author":"M Sab\u00e9","year":"2025","unstructured":"Sab\u00e9 M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry. 2025;30(3):1223\u201355.","journal-title":"Mol Psychiatry"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"694863","DOI":"10.3389\/fpsyt.2021.694863","volume":"12","author":"A Fiorentini","year":"2021","unstructured":"Fiorentini A, Cantu F, Crisanti C, Cereda G, Oldani L, Brambilla P. Substance-Induced Psychoses: An Updated Literature Review. Front Psychiatry. 2021;12:694863.","journal-title":"Front Psychiatry"},{"issue":"5","key":"1060_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","volume":"6","author":"M Di Forti","year":"2019","unstructured":"Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427\u201336.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1060_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41398-025-03654-3","volume":"15","author":"G d\u2019Andrea","year":"2025","unstructured":"d\u2019Andrea G, Chiappini S, Ciavoni L, Tucci R, Martino F, Semeraro FM, et al. Psychedelics and ketamine\/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes. Transl Psychiatry. 2025;15(1):453.","journal-title":"Transl Psychiatry"},{"key":"1060_CR23","doi-asserted-by":"crossref","unstructured":"Ricci V, Aragona M, Maina G, Martinotti G. Phenomenology of Hallucinations in Endogenous and Substance-Related Exogenous Psychoses. Psychopathology. 2025:1\u201315.","DOI":"10.1159\/000547087"},{"issue":"3","key":"1060_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/YCO.0000000000000696","volume":"34","author":"M Germann","year":"2021","unstructured":"Germann M, Brederoo SG, Sommer IEC. Abnormal synaptic pruning during adolescence underlying the development of psychotic disorders. Curr Opin Psychiatry. 2021;34(3):222\u20137.","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"1060_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1037\/pha0000084","volume":"24","author":"A Garcia-Romeu","year":"2016","unstructured":"Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol. 2016;24(4):229\u201368.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1060_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jad.2024.01.197","volume":"351","author":"L Honk","year":"2024","unstructured":"Honk L, Stenfors CUD, Goldberg SB, Hendricks PS, Osika W, Dourron HM, et al. Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom. J Affect Disord. 2024;351:194\u2013201.","journal-title":"J Affect Disord"},{"key":"1060_CR27","doi-asserted-by":"crossref","unstructured":"Krebs TS, Johansen P-O. Psychedelics and Mental Health: A Population Study. PLoS ONE. 2013;8(8).","DOI":"10.1371\/journal.pone.0063972"},{"key":"1060_CR28","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"9619","key":"1060_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(08)60505-X","volume":"371","author":"DG Altman","year":"2008","unstructured":"Altman DG, Simera I, Hoey J, Moher D, Schulz K. EQUATOR: reporting guidelines for health research. Lancet. 2008;371(9619):1149\u201350.","journal-title":"Lancet"},{"key":"1060_CR30","unstructured":"Association AP. DSM-5-TR: Diagnostic and statistical manual of mental disorders 5th ed., text rev. ed: American Psychiatric Publishing; 2022."},{"key":"1060_CR31","unstructured":"Organization WH. International classification of diseases for mortality and morbidity statistics. 11th ed. World Health Organization; 2022."},{"issue":"25","key":"1060_CR32","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1002\/sim.7411","volume":"36","author":"D Jackson","year":"2017","unstructured":"Jackson D, Law M, Rucker G, Schwarzer G. The Hartung-Knapp modification for random-effects meta-analysis: A useful refinement but are there any residual concerns? Stat Med. 2017;36(25):3923\u201334.","journal-title":"Stat Med"},{"key":"1060_CR33","unstructured":"Team RC. R: A Language and Environment for Statistical Computing. In: Computing RFfS, editor. Vienna, Austria2024."},{"issue":"6","key":"1060_CR34","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1600-0447.2010.01633.x","volume":"123","author":"N Kuzenko","year":"2011","unstructured":"Kuzenko N, Sareen J, Beesdo-Baum K, Perkonigg A, Hoefler M, Simm J, et al. Associations between use of cocaine, amphetamines, or psychedelics and psychotic symptoms in a community sample. Acta psychiatrica Scandinavica. 2011;123(6):466\u201374.","journal-title":"Acta psychiatrica Scandinavica"},{"issue":"2","key":"1060_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamapsychiatry.2024.3532","volume":"82","author":"DT Myran","year":"2025","unstructured":"Myran DT, Pugliese M, Xiao J, Kaster TS, Husain MI, Anderson KK, et al. Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder. JAMA Psychiatry. 2025;82(2):142\u201350.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"1060_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jamapsychiatry.2024.0047","volume":"81","author":"O Simonsson","year":"2024","unstructured":"Simonsson O, Mosing MA, Osika W, Ullen F, Larsson H, Lu Y, Wesseldijk LW. Adolescent Psychedelic Use and Psychotic or Manic Symptoms. JAMA Psychiatry. 2024;81(6):579\u201385.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"1060_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3109\/00952997809007016","volume":"5","author":"GG De Angelis","year":"1978","unstructured":"De Angelis GG, Goldstein E. Treatment of adolescent phencyclidine (PCP) abusers. Am J Drug Alcohol Abuse. 1978;5(4):399\u2013414.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1060_CR38","doi-asserted-by":"crossref","unstructured":"Palmer GA, Daiss DD. Personality characteristics of adolescents with hallucinogen, methamphetamine, and cannabis dependence: A comparative study. Volume 15. JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE; 2005. pp. 37\u201349. 1.","DOI":"10.1300\/J029v15n01_03"},{"issue":"7","key":"1060_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eurpsy.2009.12.002","volume":"25","author":"AH Luukkonen","year":"2010","unstructured":"Luukkonen AH, Riala K, Hakko H, Rasanen P, Study w. Bullying behaviour and substance abuse among underage psychiatric inpatient adolescents. Eur Psychiatry. 2010;25(7):382\u20139.","journal-title":"Eur Psychiatry"},{"issue":"2\u20133","key":"1060_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.schres.2009.04.005","volume":"113","author":"I Baeza","year":"2009","unstructured":"Baeza I, Graell M, Moreno D, Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, et al. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res. 2009;113(2\u20133):129\u201337.","journal-title":"Schizophr Res"},{"issue":"3","key":"1060_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/eip.12330","volume":"12","author":"S Paruk","year":"2018","unstructured":"Paruk S, Jhazbhay K, Singh K, Sartorius B, Burns JK. A comparative study of socio-demographic and substance use correlates in early-onset psychosis. Early Interv Psychiatry. 2018;12(3):339\u201347.","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"1060_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1300\/J374v04n01_06","volume":"4","author":"R Hsiao","year":"2008","unstructured":"Hsiao R, McClellan J. Substance Abuse in Early Onset Psychotic Disorders. J Dual Diagnosis. 2008;4(1):87.","journal-title":"J Dual Diagnosis"},{"issue":"6","key":"1060_CR43","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1089\/cap.2006.16.767","volume":"16","author":"G Shoval","year":"2006","unstructured":"Shoval G, Sever J, Sher L, Diller R, Apter A, Weizman A, Zalsman G. Substance use, suicidality, and adolescent-onset schizophrenia: an Israeli 10-year retrospective study. J Child Adolesc Psychopharmacol. 2006;16(6):767\u201375.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"1060_CR44","first-page":"385","volume":"20","author":"T Eseroglu","year":"2019","unstructured":"Eseroglu T, Yalcin O, Kilicoglu AG, Karacetin G. The influence of substance use disorder comorbidity on the treatment response of inpatient adolescents with the diagnosis of first episode psychosis. ANADOLU PSIKIYATRI DERGISI-ANATOLIAN J PSYCHIATRY. 2019;20(4):385\u201394.","journal-title":"ANADOLU PSIKIYATRI DERGISI-ANATOLIAN J PSYCHIATRY"},{"key":"1060_CR45","unstructured":"Digitial N, Smoking. Drinking & Drug Use among Young People in England. 2019."},{"issue":"6","key":"1060_CR46","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/archgenpsychiatry.2011.5","volume":"68","author":"M Large","year":"2011","unstructured":"Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555\u201361.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1060_CR47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","volume":"3","author":"T Schoeler","year":"2016","unstructured":"Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(3):215\u201325.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1060_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.comppsych.2006.05.002","volume":"48","author":"G Shoval","year":"2007","unstructured":"Shoval G, Zalsman G, Apter A, Diller R, Sher L, Weizman A. A 10-year retrospective study of inpatient adolescents with schizophrenia\/schizoaffective disorder and substance use. Compr Psychiatry. 2007;48(1):1\u20137.","journal-title":"Compr Psychiatry"},{"key":"1060_CR49","doi-asserted-by":"crossref","unstructured":"Ricci V, Ceci F, Di Carlo F, Lalli A, Ciavoni L, Mosca A et al. Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. Drug Alcohol Depend. 2021;229(Pt A):109118.","DOI":"10.1016\/j.drugalcdep.2021.109118"},{"key":"1060_CR50","doi-asserted-by":"publisher","first-page":"827658","DOI":"10.3389\/fpsyt.2022.827658","volume":"13","author":"P Kock","year":"2022","unstructured":"Kock P, Meyer M, Elsner J, Dursteler KM, Vogel M, Walter M. Co-occurring Mental Disorders in Transitional Aged Youth With Substance Use Disorders - A Narrative Review. Front Psychiatry. 2022;13:827658.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1060_CR51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jsat.2006.11.013","volume":"34","author":"PM Flynn","year":"2008","unstructured":"Flynn PM, Brown BS. Co-occurring disorders in substance abuse treatment: issues and prospects. J Subst Abuse Treat. 2008;34(1):36\u201347.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1060_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/wps.20894","volume":"20","author":"C Arango","year":"2021","unstructured":"Arango C, Dragioti E, Solmi M, Cortese S, Domschke K, Murray RM, et al. Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. World Psychiatry. 2021;20(3):417\u201336.","journal-title":"World Psychiatry"},{"issue":"27","key":"1060_CR53","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2174\/1381612828666220623092853","volume":"28","author":"G Martinotti","year":"2022","unstructured":"Martinotti G, Chiappini S, Mosca A, Miuli A, Santovito MC, Pettorruso M, et al. Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. Curr Pharm Des. 2022;28(27):2241\u201359.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"1060_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1176\/appi.ajp.2017.17020223","volume":"175","author":"MSK Starzer","year":"2018","unstructured":"Starzer MSK, Nordentoft M, Hjorthoj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. Am J Psychiatry. 2018;175(4):343\u201350.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1060_CR55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1017\/S0033291700030324","volume":"22","author":"S Arndt","year":"1992","unstructured":"Arndt S, Tyrrell G, Flaum M, Andreasen NC, COMORBIDITY OF SUBSTANCE-ABUSE AND SCHIZOPHRENIA - THE ROLE OF PREMORBID ADJUSTMENT. Psychol Med. 1992;22(2):379\u201388.","journal-title":"Psychol Med"},{"issue":"3","key":"1060_CR56","first-page":"1089","volume":"21","author":"DXE Lim","year":"2026","unstructured":"Lim DXE, Yeo SY, Chia ZYA, Fernandis AZ, Lee J, Chua JJE. Schizophrenia: Genetics, neurological mechanisms, and therapeutic approaches. Neural Regen Res. 2026;21(3):1089\u2013103.","journal-title":"Neural Regen Res"},{"issue":"10","key":"1060_CR57","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.tics.2015.07.008","volume":"19","author":"D Fuhrmann","year":"2015","unstructured":"Fuhrmann D, Knoll LJ, Blakemore SJ. Adolescence as a Sensitive Period of Brain Development. Trends Cogn Sci. 2015;19(10):558\u201366.","journal-title":"Trends Cogn Sci"},{"issue":"10","key":"1060_CR58","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301\u20138.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1060_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/0269881114568039","volume":"29","author":"PO Johansen","year":"2015","unstructured":"Johansen PO, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29(3):270\u20139.","journal-title":"J Psychopharmacol"},{"key":"1060_CR60","first-page":"190","volume":"6","author":"ER Butelman","year":"2015","unstructured":"Butelman ER, Kreek MJ, Salvinorin A. a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol. 2015;6:190.","journal-title":"Front Pharmacol"},{"key":"1060_CR61","volume-title":"World Drug Report 2024: Global overview of drug demand and supply","author":"Crime UNOoDa","year":"2024","unstructured":"Crime UNOoDa. World Drug Report 2024: Global overview of drug demand and supply. Vienna: UNODC; 2024."},{"key":"1060_CR62","unstructured":"European Drug Report. 2025: Trends and Developments. Luxembourg: Publications Office of the European Union: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2025."},{"issue":"11","key":"1060_CR63","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/jamapsychiatry.2023.3582","volume":"80","author":"DT Myran","year":"2023","unstructured":"Myran DT, Harrison LD, Pugliese M, Solmi M, Anderson KK, Fiedorowicz JG, et al. Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without Psychosis. JAMA Psychiatry. 2023;80(11):1169\u201374.","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"1060_CR64","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1111\/add.15987","volume":"117","author":"O Livne","year":"2022","unstructured":"Livne O, Shmulewitz D, Walsh C, Hasin DS. Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP. Addiction. 2022;117(12):3099\u2013109.","journal-title":"Addiction"},{"issue":"12","key":"1060_CR65","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81(12):1225\u201335.","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"1060_CR66","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/00048674241261779","volume":"58","author":"Z Nadeem","year":"2024","unstructured":"Nadeem Z, Parker S, McGovern H, Oestreich LK. Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. Aust N Z J Psychiatry. 2024;58(10):904\u201313.","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"1060_CR67","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s11845-021-02668-2","volume":"191","author":"K Corrigan","year":"2022","unstructured":"Corrigan K, Haran M, McCandliss C, McManus R, Cleary SD, Trant R, et al. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Ir J Med Sci. 2022;191(3):1385\u201397.","journal-title":"Ir J Med Sci"}],"container-title":["Child and Adolescent Psychiatry and Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13034-026-01060-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-026-01060-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-026-01060-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:04:35Z","timestamp":1776251075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13034-026-01060-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1186\/s13034-026-01060-1","relation":{},"ISSN":["1753-2000"],"issn-type":[{"value":"1753-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AC reports grants and personal fees from the Instituto de Salud Carlos III. She has also received research support from the Basque Government and honoraria from Janssen-Cilag, ROVI, Otsuka, Lundbeck, Viatris, and Neurotorium all outside the submitted work. C.A. is supported by the Alicia Koplowitz Foundation and has received personal fees or grants from Janssen Cilag outside the current work. GSP has received personal fees or grants from Janssen Cilag and Lundbeck outside the current work. The rest of the authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}